4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸 | 850568-49-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸
• 中文别名: 4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯硼酸；(E)-(4-(3-乙氧基-3-羰基丙-1-烯-1-基)苯基)硼酸；4-(反式-3-乙氧基-3-羰基-1-丙烯-1-基)苯硼酸
• 英文名称: (E)-(4-(3-ethoxy-3-oxoprop-1-en-1-yl)phenyl)boronic acid
• 英文别名: 4-(E-3-ethoxy-3-oxo-1-propen-1-yl)phenylboronic acid；ethyl 4-boronocinnamate；[4-[(E)-3-ethoxy-3-oxoprop-1-enyl]phenyl]boronic acid
• CAS: 850568-49-9
• 化学式: C₁₁H₁₃BO₄
• mdl: MFCD04115651
• 分子量: 220.033
• InChiKey: OVNZUEJWYIMMSW-VMPITWQZSA-N

物化性质

• 熔点：
  130-134
• 沸点：
  402.8±47.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.07
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(E-3-Ethoxy-3-oxo-1-propen-1-yl)phenylboronic acid
Product Name:
Synonyms: Ethyl 4-boronocinnamate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(E-3-Ethoxy-3-oxo-1-propen-1-yl)phenylboronic acid
Ingredient name:
CAS number: 850568-49-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H13BO4
Molecular weight: 220.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸 在 盐酸 、 二(氰基苯)二氯化钯 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 (E)-3-(4-((E)-1-(4-(1H-pyrazol-4-yl)phenyl)-2-cyclobutyl-2-phenylvinyl)phenyl)acrylic acid
  参考文献：
  名称：

  [EN] POLYCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  [FR] MODULATEURS DES RÉCEPTEURS DES ŒSTROGÈNES POLYCYCLIQUES ET LEURS UTILISATIONS

  摘要：

  本文描述了一些雌激素受体调节剂化合物。还描述了包括本文描述的化合物在内的药物组合物和药物，以及使用这些雌激素受体调节剂单独或与其他化合物结合治疗依赖于雌激素受体介导或依赖的疾病或症状的方法。

  公开号：

  WO2014151899A1
• 作为产物：
  描述：

  磷酰基乙酸三乙酯 、 4-甲酰基苯硼酸 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium chloride 作用下， 以 乙腈 为溶剂， 反应 3.67h， 以80%的产率得到4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸
  参考文献：
  名称：

  一种4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸制备方法

  摘要：

  本发明涉及医药中间体技术领域，尤其是一种4‑(E‑3‑乙氧基‑3‑氧代‑1‑丙烯‑1‑基)苯基硼酸制备方法，通过以4‑甲酰基苯硼酸为原料，经过Wittig‑Horner反应得到目标产物4‑(E‑3‑乙氧基‑3‑氧代‑1‑丙烯‑1‑基)苯基硼酸，其收率能够达到80％左右，并且采用了廉价易得的氯化锂和DBU有机试剂，避免了低温操作，反应条件温和，后处理工艺简单，适于工业化应用。

  公开号：

  CN106674263A

文献信息

• [EN] ESTROGEN RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE RÉCEPTEURS D'OESTROGÈNES ET LEURS UTILISATIONS
  申请人：SERAGON PHARMACEUTICALS INC

  公开号：WO2013142266A1

  公开（公告）日：2013-09-26

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括本文描述的化合物在内的药物组合物和药物，以及使用这些雌激素受体调节剂的方法，单独或与其他化合物结合，用于治疗与雌激素受体介导或依赖的疾病或症状。
• Diastereo-, Enantio-, and <i>Z</i>-Selective α,δ-Difunctionalization of Electron-Deficient Dienes Initiated by Rh-Catalyzed Conjugate Addition
  作者：Christopher J. C. Cooze、Wesley McNutt、Markus D. Schoetz、Bohdan Sosunovych、Svetlana Grigoryan、Rylan J. Lundgren

  DOI：10.1021/jacs.1c05427

  日期：2021.7.21

  with organoboronic acid nucleophiles and aldehyde electrophiles to generate Z-homoallylic alcohols with three stereocenters. The reaction accommodates diene substrates activated by ester, amide, ketone, or aromatic groups and can be used to couple aryl, alkenyl, or alkyl aldehydes. Diastereoselective functionalization of the Z-olefin unit in the addition products allows for the generation of compounds

  金属催化的对映选择性共轭加成是立体选择性合成的高度可靠的方法；然而，由无环 π 系统的共轭芳基化引发的多组分反应很少见。这些反应通常以较差的非对映选择性进行，同时需要碱性的、对水分敏感的有机金属亲核试剂。在这里，我们展示了由四氟苯并二甲苯配体 (Ph-tfb) 支持的 Rh 催化剂能够使缺电子的 1,3-二烯与有机硼酸亲核试剂和醛对映-、非对映-和Z-选择性 α,δ-双官能化亲电试剂产生Z-具有三个立体中心的高烯丙醇。该反应适应由酯、酰胺、酮或芳基活化的二烯底物，并可用于偶联芳基、烯基或烷基醛。加成产物中Z-烯烃单元的非对映选择性官能化允许产生具有高dr和ee 的五个立体中心的化合物. 机理研究表明醛烯丙基化是决定速率的步骤，并且与类似的 Rh-烯醇化物的反应不同，δ-芳基化产生的 Rh-烯丙基物种经历醛捕获而不是质子分解，即使当水作为共溶剂存在时也是如此。这些发现应该对使用特殊的金属催化
• ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：SMITH Nicholas D.

  公开号：US20120071535A1

  公开（公告）日：2012-03-22

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括本文所描述的化合物在内的制药组合物和药物，以及使用这些雌激素受体调节剂的方法，单独或与其他化合物结合，用于治疗由雌激素受体介导或依赖的疾病或症状。
• Estrogen receptor modulators and uses thereof
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：US08299112B2

  公开（公告）日：2012-10-30

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括上述化合物的药物组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物结合使用，治疗依赖于雌激素受体的疾病或病状的方法。
• Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
  作者：Andiliy Lai、Mehmet Kahraman、Steven Govek、Johnny Nagasawa、Celine Bonnefous、Jackie Julien、Karensa Douglas、John Sensintaffar、Nhin Lu、Kyoung-jin Lee、Anna Aparicio、Josh Kaufman、Jing Qian、Gang Shao、Rene Prudente、Michael J. Moon、James D. Joseph、Beatrice Darimont、Daniel Brigham、Kate Grillot、Richard Heyman、Peter J. Rix、Jeffrey H. Hager、Nicholas D. Smith

  DOI：10.1021/acs.jmedchem.5b00054

  日期：2015.6.25

  Approximately 80% of breast cancers are estrogen receptor alpha, (ER-a) positive, and although women typically initially respond, well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges. Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor. Fulvestrant is a steroid-based, selective estrogen receptor degrader., (SEED) That both antagonizes and degrades ER-alpha and is active in patients who have progressed on antihormonal agents. However, fulvestrant suffers from poor pharmaceutical properties and must be administered by intramuscular injections that limit the total amount of drug that can be administered and hence lead to the potential for incomplete receptor blockade. We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs, which are potent antagonists and degraders of ER-alpha and in which the ER-alpha degrading properties were prospectively optimized. The lead compound 111 (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.